Vimarsana
Biggest News Aggregation in the World

Solstice Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Solstice Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Solstice Trial Today - Breaking & Trending Today

Dr Andre on the SOLSTICE Trial in mCRC - Vimarsana News

Dr Andre on the SOLSTICE Trial in mCRC

Thierry Andre, MD, discusses the efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer and the safety profiles of the 2 arms of the phase 3 SOLSTICE trial.

Dr Andre on Survival Results From the SOLSTICE Trial in mCRC - Vimarsana News

Dr Andre on Survival Results From the SOLSTICE Trial in mCRC

Thierry Andre, MD, discusses negative overall survival results and updated safety data from the phase 3 SOLSTICE trial in metastatic colorectal cancer.

U.S. Food & Drug Administration Grants Priority Review of Maribavir for the Treatment of Post-Transplant Recipients With Cytomegalovirus Infection in Those Resistant and/or Refractory to Prior Anti-CMV Treatment - Vimarsana News

U.S. Food & Drug Administration Grants Priority Review of Maribavir for the Treatment of Post-Transplant Recipients With Cytomegalovirus Infection in Those Resistant and/or Refractory to Prior Anti-CMV Treatment

Takeda Pharmaceutical Company Limited U.S. Food & Drug Administration Grants Priority Review of Maribavir for the Treatment of Post-Transplant Recipients With Cytomegalovirus Infection in Those Resistant and/or Refractory to Prior Anti-CMV Treat Saturday, May 22, 2021 10:31AM IST (5:01AM GMT)   Osaka, Japan:    − If Approved, Maribavir Will Be the First and Only Treatment Indicated for Post-Transplant Cytomegalovirus (CMV) Infection in Those That Are Refractory, With or Without Resistance (R/R) − NDA based on Phase 3 Trial of ...